XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	₩1,314.00	+5.71%	183,197
06/08/26	₩1,243.00	+4.98%	146,805
05/08/26	₩1,184.00	+0.85%	25,651
04/08/26	₩1,174.00	+6.24%	45,881
03/08/26	₩1,105.00	+1.47%	40,714

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 07/08/2026			5-day change	1st Jan Change
1,314.00 ^KRW	+5.71%		+20.00%	-20.89%

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
21/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	22.72B 16.12M 13.95M 13.02M 11.95M 22.47M 1.53B 22.83M 153M 59.98M 769M 60.55M 59.22M 2.54B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	21.31B 15.12M 13.08M 12.21M 11.2M 21.07M 1.44B 21.4M 143M 56.23M 721M 56.76M 55.52M 2.38B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
21/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
16/07/24	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
08/07/24	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 day	+5.71%
1 week	+20.00%
Current month	+20.66%
1 month	+12.02%
3 months	-15.77%
6 months	-18.94%
Current year	-20.89%

Xcell Therapeutics Inc. Share Price

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation: Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news : Xcell Therapeutics Inc.

News in other languages: Xcell Therapeutics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,070	1,400
1 month	1,009	1,400
Current year	1,009	2,050
1 year	1,009	4,075
3 years	1,009	12,900
5 years	1,009	12,900
10 years	1,009	12,900

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	+5.71%	+20.00%	-58.81%	-	15.11M
ELI LILLY AND COMPANY	-0.79%	+3.04%	+84.71%	+160.69%	1,062B
JOHNSON & JOHNSON	+0.27%	+0.80%	+50.64%	+49.27%	619B
ABBVIE INC.	+0.64%	-2.18%	+23.44%	+63.29%	431B
ROCHE HOLDING AG	+0.71%	+3.93%	+47.75%	+38.58%	358B
NOVARTIS AG	+0.64%	-0.63%	+36.39%	+41.44%	293B
ASTRAZENECA PLC	+0.39%	-6.48%	+7.62%	+9.04%	247B
AMGEN INC.	+1.72%	+6.69%	+44.33%	+62.45%	219B
NOVO NORDISK A/S	+3.92%	-7.80%	+5.39%	-42.52%	200B
GILEAD SCIENCES, INC.	+1.45%	+2.43%	+20.95%	+65.34%	162B
Average	+1.60%	+0.18%	+26.24%	+49.73%	359.23B
Weighted average by Cap.	+0.60%	-0.83%	+48.79%	+75.85%

	2024	2025
Net sales	1.93B 1.37M 1.19M 1.11M 1.02M 1.91M 131M 1.94M 13.01M 5.11M 65.47M 5.15M 5.04M 216M	1.95B 1.38M 1.2M 1.12M 1.02M 1.93M 132M 1.96M 13.11M 5.14M 65.96M 5.19M 5.08M 218M
Net income	-9.54B -6.77M -5.86M -5.47M -5.02M -9.44M -644M -9.59M -64.17M -25.19M -323M -25.43M -24.87M -1.07B	-10.93B -7.75M -6.71M -6.26M -5.74M -10.81M -738M -10.98M -73.47M -28.84M -370M -29.11M -28.48M -1.22B
Net Debt	-3.1B -2.2M -1.9M -1.78M -1.63M -3.07M -209M -3.11M -20.85M -8.18M -105M -8.26M -8.08M -347M	-1.42B -1.01M -871K -813K -746K -1.4M -95.84M -1.43M -9.54M -3.75M -48.04M -3.78M -3.7M -159M